Lido Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Lido Advisors’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-667	Closed	-$5.42K	–	1314
2023 Q1	$5.42K	Hold	667	–	–	﹤0.01%	1143
2022 Q4	$7.91K	Hold	667	–	–	﹤0.01%	1018
2022 Q3	$9K	Hold	667	–	–	﹤0.01%	934
2022 Q2	$23K	Hold	667	–	–	﹤0.01%	919
2022 Q1	$26K	Hold	667	–	–	﹤0.01%	978
2021 Q4	$28K	Hold	667	–	–	﹤0.01%	983
2021 Q3	$45K	Hold	667	–	–	﹤0.01%	950
2021 Q2	$51K	Hold	667	–	–	﹤0.01%	894
2021 Q1	$44K	Hold	667	–	–	﹤0.01%	828
2020 Q4	$22K	Hold	667	–	–	﹤0.01%	802
2020 Q3	$37K	Hold	667	–	–	﹤0.01%	628
2020 Q2	$25K	Hold	667	–	–	﹤0.01%	594
2020 Q1	$17K	Buy	+667	New	+$28.3K	﹤0.01%	581

Other funds holding DMK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Lido Advisors's DMK Position: Q2 2023 in Review

Lido Advisors sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2023, closing a stake of 667 shares — an estimated $5.42K sold.

Lido Advisors first reported a position in DMK in Q1 2020 and held it in 13 quarters. The position peaked at $51K in Q2 2021. 22 funds tracked by Wall St. Rank hold DMK as of Q2 2023.

Lido Advisors reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2023 after selling out during the quarter.
Lido Advisors sold 667 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2023, an estimated $5.42K.
Lido Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2020 and held it in 13 quarters.
Lido Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $51K in Q2 2021.
22 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2023.

Based on Lido Advisors's 13F filing for Q2 2023, filed 9 Aug 2023.